摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-tert-butylbenzyl)-3-(2-chloro-4-hydroxy-5-methoxybenzyl)thiourea

中文名称
——
中文别名
——
英文名称
1-(4-tert-butylbenzyl)-3-(2-chloro-4-hydroxy-5-methoxybenzyl)thiourea
英文别名
1-(2-Chloro-4-hydroxy-5-methoxybenzyl)-3-(4-tert-butylbenzyl)thiourea;1-[(4-tert-butylphenyl)methyl]-3-[(2-chloro-4-hydroxy-5-methoxyphenyl)methyl]thiourea
1-(4-tert-butylbenzyl)-3-(2-chloro-4-hydroxy-5-methoxybenzyl)thiourea化学式
CAS
——
化学式
C20H25ClN2O2S
mdl
——
分子量
392.95
InChiKey
ZRDHWLDWIRMGJH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    26
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    85.6
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Halogenation of 4-hydroxy-3-methoxybenzyl thiourea TRPV1 agonists showed enhanced antagonism to capsaicin
    作者:Dong Wook Kang、HyungChul Ryu、Jeewoo Lee、Krystle A. Lang、Vladimir A. Pavlyukovets、Larry V. Pearce、Tetsurou Ikeda、Jozsef Lazar、Peter M. Blumberg
    DOI:10.1016/j.bmcl.2006.09.059
    日期:2007.1
    Selected potent TRPV1 agonists (1-6) have been modified by 5- or 6-halogenation on the aromatic A-region to analyze their effects on potency and efficacy (agonism versus antagonism). The halogenation caused enhanced functional antagonism at TRPV1 compared to the corresponding prototype agonists. The analysis of SAR indicated that the antagonism was enhanced as the size of the halogen increased (I > Br > CI) and when the 6-position was halogenated. Compounds 23c and 31b were found to be potent full antagonists with K-i (as functional antagonist) = 23.1 and 30.3 nM in rTRPV1/CHO system, respectively. (c) 2006 Elsevier Ltd. All rights reserved.
  • [EN] VANILLOID TRPV1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR VANILLOIDE TRPV1
    申请人:PHARMESTE SRL
    公开号:WO2005123666A1
    公开(公告)日:2005-12-29
    The invention relates to compounds of formula (I), wherein R e R1, R2, X and n are as defined in the description, and their use for the preparation of pharmaceutical compositions for the treatment of inflammatory states.
    该发明涉及式(I)化合物,其中R、R1、R2、X和n如描述中所定义,并且它们用于制备治疗炎症状态的药物组合物。
查看更多